Smartleaf Asset Management’s Travere Therapeutics TVTX Stock Holding History

Smartleaf Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.2K	Sell	982 -211	-18%	-$6.31K	﹤0.01%	1793
2025 Q4	$45K	Buy	1,193 +487	+69%	+$15.8K	﹤0.01%	1610
2025 Q3	$17K	Buy	706 +336	+91%	+$6.32K	﹤0.01%	1875
2025 Q2	$5.46K	Sell	370 -276	-43%	-$4.58K	﹤0.01%	2017
2025 Q1	$12.7K	Buy	646 +176	+37%	+$3.57K	﹤0.01%	1833
2024 Q4	$8.14K	Buy	470 +338	+256%	+$5.98K	﹤0.01%	2073
2024 Q3	$1.85K	Buy	132 +72	+120%	+$750	﹤0.01%	2498
2024 Q2	$496	Hold	60	–	–	﹤0.01%	2552
2024 Q1	$460	Buy	+60	New	+$506	﹤0.01%	1755

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Smartleaf Asset Management's TVTX Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Travere Therapeutics (TVTX) stake by 18% in Q1 2026, selling an estimated $6.31K and leaving 982 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Smartleaf Asset Management first reported a position in TVTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $45K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Smartleaf Asset Management held 982 shares of Travere Therapeutics worth $27.2K as of Q1 2026.
Smartleaf Asset Management sold 211 Travere Therapeutics shares in Q1 2026, an estimated $6.31K.
Travere Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1793 holding.
Smartleaf Asset Management first reported a position in Travere Therapeutics in Q1 2024 and has held it in 9 quarters since.
Smartleaf Asset Management's Travere Therapeutics position peaked at $45K in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.